Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | SLC26A4 | O43511 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24470987 | 1.00 | LMNA (0.78) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL24471000 | 0.88 | ANO1 (0.76) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL29712989 | 0.87 | LMNA (1.00) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL24470810 | 0.87 | LMNA (1.00) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL24471001 | 0.87 | SLC26A4 (0.82) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL29713104 | 0.87 | SLC26A4 (0.82) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL24470997 | 0.86 | SLC26A4 (0.80) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL29713158 | 0.86 | CASP3 (0.84) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL24470655 | 0.86 | CASP3 (0.84) | LMNAHTTSLC26A4KMT2AMEN1 | |
| SCHEMBL24485176 | 0.85 | SLC26A4 (0.75) | LMNAHTTSLC26A4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | claimed |
| EP-4259613-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2023-10-18 | — | — | EP | claimed |
| WO-2022112345-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | claimed |
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4259613-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116761796-A | Aryl derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-15 | — | — | CN | disclosed |
| WO-2022112345-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPV3, TRPM6, TRPM4 | LMNA 3256/4885HTT 2395/4885SLC26A4 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.